Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study

Movement Disorders

Volumn 26, Issue 13, 2011, Pages 2427-2431

  Altman, Robert D ^a   Lang, Anthony E ^b   Postuma, Ronald B ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Caffeine; Clinical trials; Neuroprotection; Parkinson's disease

Indexed keywords

CAFFEINE;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; TREMOR;

ADULT; AGED; AGED, 80 AND OVER; CAFFEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MIDDLE AGED; PARKINSON DISEASE; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 81955164824     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23873     Document Type: Article

References (33)

1. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000; 283: 2674-2679.
2. Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001; 50: 56-63.
3. Ascherio A, Weisskopf MG, O'Reilly EJ, et al. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 2004; 160: 977-984.
4. Ascherio A, Chen H. Caffeinated clues from epidemiology of Parkinson's disease. Neurology 2003; 61( 11 Suppl 6): S51-S54.
5. Benedetti MD, Bower JH, Maraganore DM, et al. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology 2000; 55: 1350-1358.
6. Schwarzschild MA, Chen JF, Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology 2002; 58: 1154-1160.
7. Tan EK, Tan C, Fook-Chong SM, et al. Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. J Neurol Sci 2003; 216: 163-167.
8. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002; 52: 276-284.
9. Costa J, Lunet N, Santos C, Santos J, Vaz-Carneiro A. Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies. J Alzheimers Dis 2010; 20( Suppl 1): S221-S238.
10. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006; 59: 559-562.
11. Barone JJ, Roberts HR. Caffeine consumption. Food Chem Toxicol 1996; 34: 119-129.
12. Harland BF. Caffeine and nutrition. Nutrition 2000; 16: 522-526.
13. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v3.0. 8-9-2006. Washington, DC: National Institute of Health.
14. Fahn S, Elton R, UPDRS program members. United Parkinsons Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinson's Disease, vol 2. Florham Park, NJ: Macmillan Healthcare Information; 1987: 153-163.
15. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991; 39: 142-148.
16. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-545.
17. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-1123.
18. Buysse DJ, Reynolds CF, III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213.
19. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571.
20. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56: 893-897.
21. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995; 4: 241-248.
22. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the Unified Parkinson;S Disease Rating Scale. Mov Disord 2006; 21: 1200-1207.
23. Prediger RD. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms. J Alzheimers Dis 2010; 20( Suppl 1): S205-S220.
24. Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF. Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 406-413.
25. Morelli M, Carta AR, Jenner P. Adenosine A2A receptors and Parkinson's disease. Handb Exp Pharmacol 2009; 193: 589-615.
26. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 2006; 29: 647-654.
27. Correa M, Wisniecki A, Betz A, et al. The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res 2004; 148: 47-54.
28. Wardas J, Konieczny J, Lorenc-Koci E. SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 2001; 41: 160-171.
29. Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998; 43: 507-513.
30. Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008; 70: 2233-2240.
31. LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008; 63: 295-302.
32. Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 2008; 23: 2177-2185.
33. Deleu D, Jacob P, Chand P, Sarre S, Colwell A. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease. Neurology 2006; 67: 897-899.